Diabetes can cause many complications, and has become one of the most common diseases that may lead to death. Currently, the number of diabetics continues to increase year by year. Thus, it is very important and highly desirable to monitor, control and cure diabetes. However, such management usually require long-term blood glucose monitoring and regular medication to reduce the risk of many complications. In order to provide patients with more effective and more convenient treatments, a portable, miniaturized, intelligent, painless and automatic closed-loop system is highly required and many related research studies have recently been reported. It is the right time and important to provide a summary in this field. Here, this review covers important parts of a closed-loop management system for diabetes, including the principle of electrochemical sensing of glucose, recent progress of noninvasive glucose monitoring technology, and its applications in wearable glucose sensors. Moreover, the latest advancements in an insulin delivery system and a diabetic closed-loop management system are also presented in detail. Finally, challenges and perspectives for an artificial pancreas are also presented. We believe that with the innovative glucose monitoring technology and the optimization of the drug delivery system, the closed-loop management system for diabetes will make much progress in the near future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/d2tb00749e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.
Lancet Diabetes Endocrinol
January 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address:
Background: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA levels and new-onset diabetes are conflicting. We aimed to examine the effect of oral finerenone, compared with placebo, on incident diabetes in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trial.
Methods: In this randomised, double-blind, placebo-controlled trial, 6001 participants with heart failure with New York Heart Association functional class II-IV, left ventricular ejection fraction 40% or higher, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomly assigned to finerenone or placebo, administered orally.
Ultra-sensitive, on-site pesticide detection for environmental and food safety monitoring using flexible cellulose nano fiber/Au nanorod@Ag SERS sensor.
J Hazard Mater
January 2025
Department of Mechanical, Robotics and Energy Engineering, Dongguk University, Seoul 04620, Republic of Korea. Electronic address:
This paper introduces a highly absorbent and sensitive cellulose nanofiber (CNF)/gold nanorod (GNR)@Ag surface-enhanced Raman scattering (SERS) sensor, fabricated using the vacuum filtration method. By optimizing the Ag thickness in the GNR@Ag core-shell structures and integrating them with CNFs, optimal SERS hotspots were identified using the Raman probe molecule 4-aminothiophenol (4-ATP). To concentrate pesticides extracted from fruit and vegetable surfaces, we utilized the evaporation enrichment effect using hydrophilic CNF and hole-punched hydrophobic polydimethylsiloxane (PDMS).
View Article and Find Full Text PDFAssociation of glucagon-like peptide-1 receptor agonists with acute pancreatitis and biliary disease in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
Gac Sanit
January 2025
Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain; Spanish Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Valencia, Spain.
Objective: To evaluate the risk of acute pancreatitis and biliary disease in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RA).
Method: Population-based, propensity-weighted, new user, active comparator design study including patients with diabetes and obesity initiating treatment with GLP-1 RA or the comparator group sodium-glucose cotransporter 2 inhibitors (SGLT-2i) in the region of Valencia from 2015 to 2021.
Results: In adjusted, per protocol main analysis, no risk differences were found for acute pancreatitis (HR: 0.
Digital Health Interventions for the Optimization of Postpartum Cardiovascular Health: A Systematic Scoping Review.
Am J Prev Cardiol
March 2025
Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.
Background: Digital health technologies have been proposed as a potential solution to improving maternal cardiovascular (CV) health in the postpartum (PP) period. In this context we performed a systematic scoping review of digital health interventions designed to improve PP CV health.
Methods: We conducted a systematic review of PubMed/MEDLINE, EMBASE, CINAHL, Web of Science and the Cochrane Library.
A Systematic Review and Meta-Analysis of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors and Their Impact on the Management of Heart Failure.
Cureus
December 2024
Acute Medicine, Mid and South Essex NHS Foundation Trust, Southend-on-Sea, GBR.
Heart failure (HF) is a life-threatening condition with severe incapacitating consequences. Many body organs and systems may be affected, which may also hinder the quality of life and finances at the individual and societal levels. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have also emerged as potentially useful drugs in the HF domain and other medical fields, in addition to their glucose-lowering effect.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!